SCHEMBL2476192

SCHEMBL2476192

COc1ccccc1-n1c(=O)[nH]c2nc(Nc3ccc(N4CCN(C)CC4)c(C)c3)ncc2c1=O

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LCK P06239 2/20 0.55
SRC P12931 2/20 0.55
KDR P35968 1/20 0.55
MAPK14 Q16539 1/20 0.55
TNK2 Q07912 6/20 0.53
EGFR P00533 5/20 0.52
CSF1R P07333 3/20 0.52
WEE1 P30291 2/20 0.51
KCNH2 Q12809 1/20 0.51
PDGFRB P09619 1/20 0.49
PDGFRA P16234 1/20 0.49
FLT3 P36888 2/20 0.48
TTK P33981 1/20 0.46
BRD4 O60885 1/20 0.46
BTK Q06187 1/20 0.46
PLK1 P53350 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2503488 0.91 TNK2 (0.56) LCKSRCKDRMAPK14TNK2
SCHEMBL2502950 0.91 LCK (0.59) LCKSRCKDRMAPK14TNK2
SCHEMBL2505157 0.89 TNK2 (0.54) LCKSRCKDRMAPK14TNK2
SCHEMBL2501179 0.89 TNK2 (0.54) TNK2EGFRCSF1RWEE1KCNH2
SCHEMBL12197654 0.88 TNK2 (0.54) LCKSRCKDRMAPK14TNK2
SCHEMBL2504855 0.87 WEE1 (0.63) LCKSRCKDRMAPK14TNK2
SCHEMBL2499907 0.87 TNK2 (0.54) LCKSRCKDRMAPK14TNK2
SCHEMBL2476657 0.86 TNK2 (0.55) LCKSRCKDRMAPK14TNK2
SCHEMBL2499591 0.86 TNK2 (0.54) LCKSRCKDRMAPK14TNK2
SCHEMBL2481378 0.86 SLC2A1 (0.57) LCKSRCKDRMAPK14TNK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8575179-B2 Dihydropyrazolopyrimidinone derivatives MSD K.K. (JP) 2013-11-05 US claimed
EP-2376494-A1 DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVES MSD K.K. (JP) 2011-10-19 EP claimed
US-20110245229-A1 DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES MSD K.K. (JP) 2011-10-06 US claimed
WO-2010067888-A1 DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVES BANYU PHARMACEUTICAL CO.,LTD. (JP) 2010-06-17 WO claimed
US-8575179-B2 Dihydropyrazolopyrimidinone derivatives MSD K.K. (JP) 2013-11-05 US disclosed
US-8575179-B2 Dihydropyrazolopyrimidinone derivatives MSD K.K. (JP) 2013-11-05 US disclosed
US-8575179-B2 Dihydropyrazolopyrimidinone derivatives MSD K.K. (JP) 2013-11-05 US disclosed
EP-2376494-A1 DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVES MSD K.K. (JP) 2011-10-19 EP disclosed
US-20110245229-A1 DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES MSD K.K. (JP) 2011-10-06 US disclosed
US-20110245229-A1 DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES MSD K.K. (JP) 2011-10-06 US disclosed
WO-2010067888-A1 DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVES BANYU PHARMACEUTICAL CO.,LTD. (JP) 2010-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110245229-A1 DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES WEE2, WEE1, CDKL1 LCK 478/4885SRC 492/4885KDR 1115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.